The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Combination of dabrafenib (DAB) and lapatinib (LAP) for the treatment of BRAF-mutant thyroid cancer.
 
Eric Jeffrey Sherman
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Loxo; Novartis
Research Funding - Eisai; Plexxikon; Roche/Genentech
 
Alan Loh Ho
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Genzyme; Kura Oncology; Merck; Novartis; Novartis; oncology consortium; Regeneron; Sun Pharma; Sun Pharma; TRM Oncology
Speakers' Bureau - Medscape; Omniprex America
Research Funding - Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Genentech/Roche; Kolltan Pharmaceuticals; Kura Oncology; Lilly
Travel, Accommodations, Expenses - Ignyta; Janssen Oncology; Kura Oncology; Merck
 
James A. Fagin
No Relationships to Disclose
 
Sofia Haque
No Relationships to Disclose
 
Crystal Robinson
No Relationships to Disclose
 
Ronald A. Ghossein
No Relationships to Disclose
 
Helen X. Chen
No Relationships to Disclose
 
David G. Pfister
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - AstraZeneca; Bayer; Boehringer Ingelheim; Exelixis; Genentech/Roche; Incyte; Lilly; MedImmune; Merck; Novartis